Pfizer

Structure

One of Pfizer's divisions is Pfizer Injectables - it specializes in drug injection systems.

Performance indicators

2023: On the list of companies with the largest R&D costs

The chart shows 12 months of data as of April 2023.
For Amazon shows the costs of technology and content (not R&D).
ByteDance statistics date back to 2021 (according to the Wall Street Journal)

2021

Waiting for record annual vaccine sales of $33.5 billion

Pfizer Inc. expects its Covid-19 vaccine to generate $33.5 billion in revenue in 2021, allowing it to become one of the best-selling drugs ever.

Sales of vaccines against COVID-19 in 3 months reached $3.5 billion

In early May 2021, it became known that Pfizer received more than $3 billion from sales of the coronavirus vaccine in the first three months of the year. Revenue from the sale of the vaccine is expected to be $26 billion by the end of the year.

Sales of the coronavirus vaccine in the United States and other countries of the world accounted for almost a quarter of the company's revenue for the first quarter ($14.6 billion). Pfizer expects to deliver a total of 1.6 billion doses of the vaccine in 2021, which will bring it income of $26 billion, while according to the first forecasts, the company expected only $15 billion. Pfizer's total revenue is expected to grow to $70.5-72.5 billion in 2021.

Pfizer sold $3.5 billion in coronavirus vaccines in three months of 2021

Additional revenue from the sale of the vaccine is likely to continue into 2022. In April, Pfizer CEO Albert Bourla said that 12 months after the first dose, all vaccinated people may need revaccination. The company has already stated that in 2022 it will have the opportunity to produce 3 billion doses.

We believe that the data available to date predict a steady demand for our COVID-19 vaccine in 2022, Burla said in a special comment before talking with investors.

Pfizer did not specify the figures for net profit from the sale of the vaccine, but it is likely that it will be over 20%. This means a net profit of about $900 million from January to March and up to $6.5 billion per year. BioNTech, the German biotech firm that helped develop Pfizer's vaccine, could also make billions in profits from vaccine sales.

Other pharmaceutical companies, such as Johnson & Johnson and AstraZeneca, have pledged not to appropriate profits from their vaccines until the pandemic is brought under control. Pfizer said it would not profit from the sale of its vaccine to the world's poorest countries.^[1]

Business in Russia

Main article: Pfizer Innovation

History

2024: How Pfizer orchestrated collusion to keep cheap drugs off the market

In mid-February 2024, Pfizer agreed to pay $93 million in antitrust proceedings initiated by wholesale distributors of drugs. The company is accused of conspiring with the Indian Ranbaxy to curb sales of inexpensive analogues of the Lipitor tool.

"Lipitor" is designed to lower blood cholesterol levels. preparation refers to third generation lipid-lowering agents of statin group. It is often prescribed to patients suffering from cardiovascular pathologies. The substance is only recommended for use after other measures such as diet, exercise and weight loss have not helped improve cholesterol levels sufficiently.

𝓲

Unsplash

Pfizer introduced Lipitor in 1997, and in the first 14 years of its presence on the market, sales of the drug exceeded $130 billion. The lawsuit alleges Pfizer paid Ranbaxy to delay the release of the drug's affordable generics. In addition, Pfizer is alleged to have been involved in a sham lawsuit with Ranbaxy over the drug. Distributors say Pfizer used fraudulent methods to extend the terms of patent rights for the drug.

At the same time, Pfizer rejects claims against it. The company calls the allegations "factually and legally unfounded." At the same time, the settlement agreement is for Pfizer "a reasonable and most effective way to resolve this antitrust conflict." The decision, which requires the approval of a judge, comes after more than a decade of litigation. The process for Ranbaxy as of mid-February 2024 is ongoing. Sun Pharma, which acquired Ranbaxy in 2014, does not comment on the situation.^[2]

2023

Seagen purchase for $43 billion

On March 3, 2023, Pfizer Pharmaceutical Corporation announced an agreement to acquire the biotechnology company Seagen. The transaction will be carried out in cash at the rate of $229 for one Seagen security, and the total amount will be approximately $43 billion. Read more here.

Charge of artificially excreting viruses to sell vaccines

At the end of January 2023, journalists from Project Veritas stated that Pfizer allegedly specifically creates variants of coronavirus (COVID-19) infection in its laboratories in order to create updated vaccines for their treatment.

Project Veritas released a video of the alleged Pfizer employee on January 25, 2023. Veritas founder James O'Keefe said he had information to confirm that alleged employee Jordan Walker is indeed an employee of Pfizer, who holds the position of "Director of Strategic Operations for Research and Development and Scientific Planning of Matrix Ribonucleic Acid (MRNA)."

Pfizer accused of artificially eliminating viruses to sell vaccines

According to former Pfizer employee Jordan Walker, Pfizer's secure laboratories are experimenting with infected coronavirus infection (COVID-19) cells. The company is trying to find out whether the main protease can mutate and lead to the formation of resistant variants of the COVID-19 virus. According to him, there are separate elements in the SARS CoV-2 spike protein that other related coronaviruses do not have, and this is used by scientists from Pfizer for artificial cell mutation. At the same time, Walker clarifies that individual types of mutations are also involved in the experiments, which were naturally derived due to the ability of COVID-19 viruses to rebuild and change during natural evolution when moving from one host to another. Pfizer is actively studying various changes in the RNA and DNA of the virus from the East of Europe, from Southeast Asia, where it is wet and warm, which leads to the emergence of updated subspecies of COVID-19.

Pfizer said that during the development of a vaccine against COVID-19, the company did not conduct research related to the "directed evolution" of the virus or its acquisition of any new features. At the same time, the company reports that Pfizer conducted tests in which "the original SARS-CoV-2 virus was used to express a spike protein from new variants of COVID-19." According to Pfizer, without such studies, it will not be possible to test the effectiveness of the vaccine against new varieties of COVID-19.^[3]

2022

Using Digital Technology to Develop Drugs

In early December 2022, during one of the conferences, Pfizer representatives spoke about digital innovations that help the company develop promising drugs and transform the pharmaceutical industry.

It is noted that due to the pandemic and the current macroeconomic situation, advanced digital technologies have become an integral part of the business model for many companies, while they were previously considered as auxiliary solutions. In particular, we are talking about cloud platforms, on the basis of which many workloads are performed in various areas, including healthcare. Pfizer also uses clouds to speed up and optimize its processes. But as of 2021, only about 10% of Pfizer's infrastructure has been placed in the public cloud.

What digital technologies Pfizer is using to develop drugs

The company is using so-called "computational chemistry" to create new drugs, according to Wes Barnes, senior executive at Pfizer Digital Solutions. The research process involves machine learning tools and big data analytics.

Шаблон:Quote 'We cannot release drugs without the use of technology. One of the key areas of our research is computational chemistry, "Barnes said. Pfizer is rolling out digital solutions in other areas as well. So, it became one of the first pharmaceutical companies that began to use radio frequency identification (RFID) technology when packing goods. In addition, Pfizer applies safety monitoring systems for all products both at the stage of their development and at the stage when the drug is already approved for use in general medical practice and is on sale. In general, the introduction of corporate computing in the biomedical field helps in providing patients with better products and services.^[4]

Pfizer acquires ResApp for $116 million

At the end of September 2022, the pharmaceutical giant Pfizer announced the purchase of a developer of a mobile application for detecting coronavirus for $116 million, which can accurately diagnose COVID-19 by analyzing the sound of a cough. We are talking about ResApp, which since 2012 has been developing an algorithm that can diagnose respiratory diseases by simply studying the sound of a patient coughing. The system was initially trained to diagnose pneumonia, but by 2019, researchers showed the technology could effectively distinguish between asthma, croup and bronchiolitis. Read more here.

Purchase of a developer of drugs for the treatment of blood diseases for $5.4 billion

On August 8, 2022, Pfizer announced the purchase of Global Blood Therapeutics, a manufacturer of a drug for sickle cell disease (hereditary blood disease), in a deal worth $5.4 billion. Read more here.

Buying a stake in Valneva, which develops vaccines against COVID-19

In June 2022, it announced the sale of a stake in Valneva to Pfizer. The latter plans to start a phase 3 study of the VLA15 vaccine, which Valneva is developing, in the third quarter of 2022. Read more here.

Purchase of Biohaven for $11.6 billion

In early May 2022, Pfizer announced the purchase of migraine drug manufacturer Biohaven for $11.6 billion. The deal gives Pfizer control of a large portfolio of peptide drugs linked to the calcitonin gene. The purchase is expected to be completed in early 2023. Read more here.

Purchase of ReViral for $525 million

On April 7, 2022, it became known that Pfizer agreed to acquire the developer of antiviral drugs for the treatment of respiratory diseases ReViral for $525 million, which was another step by the manufacturer of Covid-19 vaccines in the market for technologies to combat infectious diseases. Read more here.

Recall of high pressure drug Accuretic

At the end of March 2022 Pfizer , recalls several drugs from blood pressure due to the increased content of nitrosamine, which can increase the risk of development. cancer More. here

2021

Buying auto-immune drug developer Arena Pharmaceuticals

On December 13, 2021, Pfizer announced the purchase of Arena Pharmaceuticals, which is in the clinical stage of developing innovative potential therapies to treat a number of immunoinflammatory diseases. Under the terms of the agreement, Pfizer will acquire all outstanding Arena shares at a price of $100 per share, the total value of the shares will be about $6.7 billion. The boards of directors of both companies unanimously approved the deal. The deal is expected to close in the first half of 2022. Read more here.

Recall of anti-smoking drug Chantix

At the end of September 2021, Pfizer voluntarily recalls all batches of its popular anti-smoking drug Chantix due to its high nitrosamine content, which can increase the risk of cancer. Wholesalers and distributors with stocks of tablets should immediately stop using and distributing them and quarantine the product. Read more here.

$2.26 billion purchase of Trillium Therapeutics

On August 23, 2021, Pfizer Inc. and Trillium Therapeutics Inc. announced that Pfizer is acquiring Trillium, an immuno-oncology clinical stage company developing innovative cancer therapies.

Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium, which are not yet owned by Pfizer, for an estimated share value of $2.26 billion, or $18.50 per share.

DPRK hackers attack Pfizer to sell clandestine COVID-19 vaccine

In mid-February 2021 the North Korean hackers , they tried to hack Pfizer's computer systems pharmaceutical in search of information to vaccine about and technology (). treatment of coronavirus infection COVID-19 This became known on February 25, 2021.

It became known that the attackers intended to use scientific data to sell a counterfeit vaccine against COVID-19 in international black markets. This was reported by representatives of the European special services to Business Insider.

The hacking attempt was allegedly part of an official North Korean operation to collect scientific data on Pfizer's COVID-19 vaccine, one of three vaccines approved for emergency use by the World Health Organization.

The source recalled that earlier the Ministry of Justice USA charged three hackers from the DPRK with conducting a large-scale one, as cyber attacks a result of which more than $1.3 billion was stolen, including to cryptocurrency^[5]

In Israel, 13 people received facial paralysis after vaccination with Pfizer

In mid-January 2021, it became known about the negative consequences of the introduction of the COVID-19 coronavirus vaccine developed by Pfizer. In Israel, 13 residents after vaccination experienced facial paralysis.

According to The Jerusalem Post, citing the country's Ministry of Health, the agency does not exclude similar symptoms in more vaccinated people. In Mizdrava, Israel added that everyone who developed similar symptoms after the first dose should postpone the second vaccination until recovery.

Mass vaccination started in the country at the end of December 2020. On January 14, 2021, the Israeli Ministry of Health reported that out of 2 million people vaccinated with the first dose of Pfizer, 1,127 people faced negative consequences.

In Israel, 13 people received facial paralysis after vaccination with Pfizer coronavirus drug

Most frightening was Bell's palsy, a syndrome of temporary muscle spasm on one side of the face. Several more vaccinated declared a strange metallic taste in the mouth. Two reported that they had difficulty breathing, another person lost consciousness after the injection.

One of the residents who passed the first stage of vaccination shared that he noticed unusual sensations in the oral cavity and in the chin area a couple of minutes after the injection.

For at least 28 hours I went with this [facial paralysis]. I can't say that now it has completely passed, but besides this nothing else bothered me, only the place of the injection was a little sore, and that's it, "said an Israeli who faced temporary facial paralysis after vaccination.

Now, after the appearance of signs of facial paralysis in patients, doctors argue about the advisability of undergoing the second stage of vaccination with paresis.

At the first stage of vaccination in Israel, health workers, medical students, employees of geriatric institutions and authorities representatives were vaccinated. At the second stage, they began to vaccinate people over 60 years old and those who are at risk.^[6]

2020: Pfizer CEO sells 60% of the company's shares on the day the results of the coronavirus vaccine trial are announced

In mid-November 2020, the CEO Pfizer Albert Bourla sold 62% of his stake in the company on the same day Pfizer announced the test results. In COVID-19 vaccines total, Burla sold $5.6 million worth of shares at a price of $41.94 per dollar share. It is known that the CEO cashed in his shares at a price that was approaching the maximum value of the shares in 2020. More. here

2019: Dismissal of the claim against Nativa LLC for the use of Sunitinib-nativ

On October 24, 2019, in the Intellectual Rights Court, a cassation appeal was heard on the claim of Pharmasia and Upjohn Campani LLC and Susan Ink LLC, which are members of the Pfizer group, to LLC Nativa and. Ministry of Health of the Russian Federation This became known on October 28, 2019. The court refused to satisfy the claim in the case of A40-166505/17 in favor of Nativa. The demand of foreign companies to ban the use, manufacture and sale Russian of an antitumor drug with the trade name Sunitinib-nativ was rejected. And the counter-demand of Nativa to issue a license for the use of the invention, protected by Eurasian patent No. 005996 for the production of its own drugs of Nativa, is satisfied. More. here

2018: Albert Burla - new CEO

On October 1, 2018, Pfizer announced a change of CEO. He became Albert Burla, who will replace Ian Read, who led the company for eight years. Read more here.

Notes